NCT05126784View on ClinicalTrials.gov

AVT03 With Prolia in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions
Healthy Male Subjects
Interventions
BIOLOGICAL

AVT03

AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection

BIOLOGICAL

Prolia

Prolia (denosumab) will be given as single subcutaneous injection

Trial Locations (4)

Unknown

Nucleus Network, Herston

NZCR Christchurch, Christchurch

NZCR Auckland, Auckland

Farmovs, Bloemfontein

All Listed Sponsors
lead

Alvotech Swiss AG

INDUSTRY